Related Experiment Video
Updated: Jun 21, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
The Par-4/PTEN connection in tumor suppression
Maria T Diaz-Meco1, Shadi Abu-Baker
1Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA. maria.diazmeco@uc.edu
Loss of tumor suppressor Par-4, often seen with PTEN loss in prostate cancer, drives tumor progression. Restoring both Par-4 and PTEN pathways may offer new cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Tumor suppressors are crucial for preventing cancer by functioning within coordinated regulatory networks.
- Inactivation of tumor suppressors is a critical event in the development of cancer.
- The tumor suppressor Par-4 is identified as a key component within the PTEN regulatory network.
Purpose of the Study:
- To investigate the role of the tumor suppressor Par-4 in prostate cancer development and progression.
- To elucidate the relationship between Par-4 and PTEN in the context of prostate carcinogenesis.
- To explore the therapeutic potential of targeting complementary signaling pathways in prostate cancer.
Main Methods:
- Analysis of Par-4 expression in human prostate carcinomas.
- Genetic ablation of Par-4 in PTEN-heterozygous mice models.
- Assessment of prostate intraepithelial neoplasia (PIN) progression and invasive carcinoma development.
- Investigation of signaling pathways including Akt and NF-kappaB activation.
Main Results:
- Par-4 is frequently absent in human prostate carcinomas, correlating with PTEN loss.
- Genetic deletion of Par-4 in PTEN-heterozygous mice leads to invasive prostate carcinomas.
- Par-4 deficiency alone or PTEN heterozygosity results in non-progressive benign neoplastic lesions (PIN).
- Simultaneous inactivation of Par-4 and PTEN enhances Akt activation and synergistically activates NF-kappaB.
- A regulatory feedback loop between Par-4 and PTEN is identified at the PIN transition stage, crucial for preventing cancer progression.
Conclusions:
- Par-4 deficiency cooperates with PTEN haploinsufficiency in prostate cancer initiation and progression.
- The simultaneous loss of Par-4 and PTEN activates unique synergistic mechanisms involving PI3K/Akt and NF-kappaB pathways.
- Targeting both PI3K/Akt and NF-kappaB signaling pathways concurrently presents a promising therapeutic strategy for prostate cancer.
Related Concept Videos
Abnormal Proliferation
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
